Literature DB >> 16393993

Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation.

Jacques Chapiro1, Stéphane Claverol, Fanny Piette, Wenbin Ma, Vincent Stroobant, Benoît Guillaume, Jean-Edouard Gairin, Sandra Morel, Odile Burlet-Schiltz, Bernard Monsarrat, Thierry Boon, Benoît J Van den Eynde.   

Abstract

The immunoproteasome (IP) is usually viewed as favoring the production of antigenic peptides presented by MHC class I molecules, mainly because of its higher cleavage activity after hydrophobic residues, referred to as the chymotrypsin-like activity. However, some peptides have been found to be better produced by the standard proteasome. The mechanism of this differential processing has not been described. By studying the processing of three tumor antigenic peptides of clinical interest, we demonstrate that their differential processing mainly results from differences in the efficiency of internal cleavages by the two proteasome types. Peptide gp100(209-217) (ITDQVPSFV) and peptide tyrosinase369-377 (YMDGTMSQV) are destroyed by the IP, which cleaves after an internal hydrophobic residue. Conversely, peptide MAGE-C2(336-344) (ALKDVEERV) is destroyed by the standard proteasome by internal cleavage after an acidic residue, in line with its higher postacidic activity. These results indicate that the IP may destroy some antigenic peptides due to its higher chymotrypsin-like activity, rather than favor their production. They also suggest that the sets of peptides produced by the two proteasome types differ more than expected. Considering that mature dendritic cells mainly contain IPs, our results have implications for the design of immunotherapy strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16393993     DOI: 10.4049/jimmunol.176.2.1053

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  64 in total

1.  Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules.

Authors:  Danielle de Verteuil; Tara L Muratore-Schroeder; Diana P Granados; Marie-Hélène Fortier; Marie-Pierre Hardy; Alexandre Bramoullé; Etienne Caron; Krystel Vincent; Sylvie Mader; Sébastien Lemieux; Pierre Thibault; Claude Perreault
Journal:  Mol Cell Proteomics       Date:  2010-05-19       Impact factor: 5.911

2.  Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoire.

Authors:  Nicholas J Steers; Jeffrey R Currier; Gustavo H Kijak; Robert C di Targiani; Ashima Saxena; Mary A Marovich; Jerome H Kim; Nelson L Michael; Carl R Alving; Mangala Rao
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

3.  Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.

Authors:  Benoît Guillaume; Jacques Chapiro; Vincent Stroobant; Didier Colau; Benoît Van Holle; Grégory Parvizi; Marie-Pierre Bousquet-Dubouch; Ivan Théate; Nicolas Parmentier; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

Review 4.  Database of T cell-defined human tumor antigens: the 2013 update.

Authors:  Nathalie Vigneron; Vincent Stroobant; Benoît J Van den Eynde; Pierre van der Bruggen
Journal:  Cancer Immun       Date:  2013-07-15

Review 5.  Immunoproteasomes: structure, function, and antigen presentation.

Authors:  Deborah A Ferrington; Dale S Gregerson
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

6.  Computational prediction of cleavage using proteasomal in vitro digestion and MHC I ligand data.

Authors:  Yu-feng Lu; Hao Sheng; Yi Zhang; Zhi-yang Li
Journal:  J Zhejiang Univ Sci B       Date:  2013-09       Impact factor: 3.066

7.  Major Histocompatibility Complex (MHC) Class I Processing of the NY-ESO-1 Antigen Is Regulated by Rpn10 and Rpn13 Proteins and Immunoproteasomes following Non-lysine Ubiquitination.

Authors:  Richard Golnik; Andrea Lehmann; Peter-Michael Kloetzel; Frédéric Ebstein
Journal:  J Biol Chem       Date:  2016-02-22       Impact factor: 5.157

Review 8.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

9.  An antigenic peptide produced by reverse splicing and double asparagine deamidation.

Authors:  Alexandre Dalet; Paul F Robbins; Vincent Stroobant; Nathalie Vigneron; Yong F Li; Mona El-Gamil; Ken-ichi Hanada; James C Yang; Steven A Rosenberg; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

10.  Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus.

Authors:  Michael D Robek; Mayra L Garcia; Bryan S Boyd; Francis V Chisari
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.